Electro-Optical bags $11.5m funding:
This article was originally published in Clinica
Manufacturer of the MelaFind non invasive melanoma diagnosis tool Electro-Optical Sciences (Irvington, New York) has secured $11.5m in a private placement from institutional investors. The funding, invested by Cowen and Company and ThinkEquity Partners, comprised just over 2 million common shares priced at $5.75 per share and around 500,00 common stock warrants that are exercisable at $8.00 for 54 months beginning six months after the closing of the investment. The company will use the proceeds to further the design and development of MelaFind, which emits multiple wavelengths to capture images of suspicious pigmented skin lesions, and extract data which can be analysed to tell physicians whether or not a lesion should be biopsied.
You may also be interested in...
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.